SABE belle BIOMALIFE® BAXTERBIOMA capsules, 60 ST

Image/color similar

SABE belle BIOMALIFE® BAXTERBIOMA capsules are a food supplement based on Limosilactobacillus reuteri Pylopass™.

€31.50

Content: 60 Stück (€0.53 / 1 Stück)

(May vary by country)

Available, delivery time: 1-3 days ⁴

Product number: RA8078266

Stück: 60

Manufacturer: SABE belle

Product information "SABE belle BIOMALIFE® BAXTERBIOMA capsules"

SABE belle BIOMALIFE® BAXTERBIOMA capsules are a food supplement based on Limosilactobacillus reuteri Pylopass™.

Helicobacter pylori

H. pylori is a bacterium found in the human stomach. It tolerates acidic pH levels very well, as it produces ammonia. Furthermore, thanks to its spiral-shaped structure, it is able to penetrate the mucous layer and anchor itself to the inner stomach wall, where the acidity is lower. H. pylori infection is the most significant risk factor for chronic gastritis and a contributing factor to peptic ulcers (stomach ulcers), which are severe, localised lesions of the mucous membrane of the digestive tract. Certain factors increase the risk of this type of infection: a family history of the condition, cigarette smoking and severe stress.

Helicobacter pylori infection is diagnosed by means of:

Blood test
Stool test
Breath test

Typical symptoms of chronic gastritis include: pain in the upper abdomen, a feeling of fullness, nausea, vomiting, belching, loss of appetite, weight loss and indigestion (or poor digestion). Chronic gastritis can also be completely asymptomatic (around 20 per cent of cases).

Active ingredients

PYLOPASS™: Several clinical studies have shown that the eradication of H. pylori is more successful in patients who, in addition to pharmacological treatment, also take dietary supplements containing specific probiotic strains. One such strain is Pylopass™, a tyndallised strain of Limosilactobacillus reuteri. Pylopass™ binds specifically and selectively to H. pylori without affecting other bacterial strains in the gut microbiota. Each unit of L. reuteri binds 2–3 H. pylori bacteria. Thanks to this binding, H. pylori cannot adhere to the gastric mucosa and is excreted more easily.

In vivo studies demonstrate that Pylopass™ reduces the bacterial load of H. pylori, alleviates symptoms and increases the eradication rate of this bacterium in people undergoing pharmacological treatment.

Efficacy study

For the clinical trial by Parth (2021), 90 patients were divided into two groups. One group received triple eradication therapy with L. reuteri Pylopass™ for 14 days, whilst the other group received triple antibiotic therapy alone.
The following reduction in the most significant side effects of the eradication therapy was observed: nausea (60% vs. 86.67%, p=0.033), diarrhoea (36.6% vs. 50%, p=0.035), constipation (20% vs. 33.3%, p=0.026), and changes in taste (43.3% vs. 60%, p=0.047).
Patients treated with Pylopass™ in combination with antibiotic therapy also show statistically significant improvements in symptoms caused by the infection, such as stomach pain, heartburn, acid reflux, nausea, bloating and belching.
The eradication rate reported in the study rose from 66.67% (group receiving triple antibiotic therapy) to 86.67% (group receiving triple antibiotic therapy and Pylopass™).

Notes

Gluten-free
Naturally lactose-free
No sweeteners
No added sugar
No preservatives

• C. Holz, ‘Significant Reduction in Helicobacter pylori load in Humans with Non-viable Lactobacillus reuteri DSM17648: A Pilot Study’, Probiotics & Antimicro. Prot., 2014. • H. Mehling, “Non-viable Lactobacillus reuteri DSMZ 17648 (Pylopass™) as a new approach to Helicobacter pylori control in humans”, Nutrients, 2013, 5, 3062–3073. • M.H. Emara, “Lactobacillus reuteri in the management of Helicobacter pylori infection in dyspeptic patients: a double-blind, placebo-controlled, randomised clinical trial”, Ther Adv Gastroenterol 2014, Vol 7(1) 4–13. • Lonza, “Pylopass™: A New Approach to H. pylori Control – Raw Material Presentation”, 2012. • Network Nutrition – IMCD, “Raw Material Brochure”. • K. Parth et al., “Efficacy of Lactobacillus reuteri Supplementation in the Eradication of H. pylori: A Comparison Study with Triple Drug Therapy”, JPRI, 33(52B): 151–159, 2021.

Dosage form

Tablets

Directions for use

Take 2 capsules daily with a large glass of water. Preferably take one capsule after breakfast and one capsule after dinner.
Notes: Suitable for children. Safe for use during pregnancy and whilst breastfeeding.

Ingredients

Ingredients: FILLERS: CELLULOSE, DICALCIUM PHOSPHATE; LIMOSILACTOBACILLUS REUTERI DSM 17648 (NON-LIVE CELLS, MALTODEXTRIN); COATING AGENT (CAPSULE): HYDROXYPROPYLMETHYLCELLULOSE; ANTI-CAKING AGENTS: MAGNESIUM SALTS OF FATTY ACIDS, SILICON DIOXIDE; COLOURING AGENT: CALCIUM CARBONATE.
Composition per daily dose (2 capsules): L. reuteri Pylopass™* 200 mg (equivalent to^2×10¹⁰ inactivated cells). *Pylopass™ is a trademark of Novozymes A/S, Denmark.

Gluten-free:	Yes
Lactose-free:	Yes
Piece:	60
Vegetarian:	Yes

Instructions for use

Product recommendations for you

Our recommendation

15.03 %

SABE belle REFLUXcontrol sticks

SABE belle REFLUXcontrol Sticks are a medical device for oral use for the treatment of gastro-oesophageal reflux, heartburn, oesophagitis, irritable cough and belching due to gastric reflux.

Sofort verfügbar

Content: 20 Stück

€14.36* €16.90*

15 %

SABE belle REFLUXcontrol chewable tablets

SABE belle REFLUXcontrol chewable tablets are a medical product that reduces gastro-oesophageal reflux, relieves gastric acidity and protects the gastric mucosa.

Sofort verfügbar

Content: 24 Stück

€7.99* €9.40*

SABE belle BIOMALIFE® BAXTERBIOMA capsules, 60 ST

Dosage form

Directions for use

Ingredients

Instructions for use

We stay in touch!